A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients FINE Trial

Creative Commons License

Akman Demir G., Turkoglu R., SAİP S., YÜCEYAR A. N., EFENDİ H., TURAN Ö. F., ...More

NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, vol.56, no.4, pp.253-257, 2019 (SCI-Expanded, Scopus, TRDizin)

  • Publication Type: Article / Article
  • Volume: 56 Issue: 4
  • Publication Date: 2019
  • Doi Number: 10.5152/npa.2017.20515
  • Journal Name: NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.253-257
  • Keywords: Multiple sclerosis, fingolimod, patient satisfaction, quality of life, ORAL FINGOLIMOD, INTRAMUSCULAR INTERFERON, DOUBLE-BLIND, SAFETY, THERAPIES, EFFICACY, OUTCOMES, ACETATE, PHASE-3, SWITCH
  • Open Archive Collection: AVESIS Open Access Collection
  • Ondokuz Mayıs University Affiliated: Yes

Abstract

Introduction: To assess satisfaction and quality of life in patients with relapsing-remitting multiple sclerosis (RRMS) who were receiving fingolimod (0.5 mg/day) for 12 months as a second-line treatment after switching from injectable agents.